Research Progress on the Correlation between Acetaldehyde Dehydrogenase 2 and Hepatocellular Carcinoma Development
The Journal of Pharmacology and Experimental Therapeutics · 2024
DOI: 10.1124/jpet.123.001898 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2024. Verfasst von Dashuai Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China (D.Y., L.T.…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Aldehyde Oxidoreductases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 111 Literaturangaben.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is the predominant pathologic type of primary liver cancer. It is a malignant tumor of liver epithelial cells. There are many ways to treat HCC, but the survival rate for HCC patients remains low. Therefore, understanding the underlying mechanisms by which HCC occurs and develops is critical to explore new therapeutic targets. Aldehyde dehydrogenase 2 (ALDH2) is an important player in the redox reaction of ethanol with endogenous aldehyde products released by lipid peroxidation. Increasing evidence suggests that ALDH2 is a crucial regulator of human tumor development, including HCC. Therefore, clarifying the relationship between ALDH2 and HCC is helpful for formulating rational treatment strategies. This review highlights the regulatory roles of ALDH2 in the development of HCC, elucidates the multiple potential mechanisms by which ALDH2 regulates the development of HCC, and summarizes the progress of research on ALDH2 gene polymorphisms and HCC susceptibility. Meanwhile, we envision viable strategies for targeting ALDH2 in the treatment of HCC SIGNIFICANCE STATEMENT: Numerous studies have aimed to explore novel therapeutic targets for HCC, and ALDH2 has been reported to be a critical regulator of HCC progression. This review discusses the functions, molecular mechanisms, and clinical significance of ALDH2 in the development of HCC and examines the prospects of ALDH2-based therapy for HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei, Anhui, China (D.Y., L.T., Y.W., Y.Y., S.W., T.X.); Institute for Liver Diseases of Anhui Medic…
ORCID-Profile: Dashuai Yang, Ying Hu, Junfa Yang, Liangsong Tao, Yue Su, Yincui Wu, Yan Yao, Shuxian Wang, Sheng Ye, Tao Xu
Zitieren
APA
Yang, D., Hu, Y., Yang, J., Tao, L., Su, Y., Wu, Y., Yao, Y., Wang, S., Ye, S., & Xu, T. (2024). Research Progress on the Correlation between Acetaldehyde Dehydrogenase 2 and Hepatocellular Carcinoma Development. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1124/jpet.123.001898
Vancouver
Yang D, Hu Y, Yang J, Tao L, Su Y, Wu Y, et al. Research Progress on the Correlation between Acetaldehyde Dehydrogenase 2 and Hepatocellular Carcinoma Development. The Journal of Pharmacology and Experimental Therapeutics. 2024. doi:10.1124/jpet.123.001898
BibTeX
@article{Yang2024,
author = {Yang, Dashuai and Hu, Ying and Yang, Junfa and Tao, Liangsong and Su, Yue and Wu, Yincui and Yao, Yan and Wang, Shuxian and Ye, Sheng and Xu, Tao},
title = {Research Progress on the Correlation between Acetaldehyde Dehydrogenase 2 and Hepatocellular Carcinoma Development},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
year = {2024},
doi = {10.1124/jpet.123.001898}
}
EUVIMED